Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same

Abstract

A solid phase synthesis method for preparing peptide-spacer-lipid conjugates, the peptide-spacer-lipid conjugates synthesized by the method, and liposomes containing the peptide-spacer-lipid conjugates. The present invention provides a convenient solid phase synthesis method for preparing peptide-spacer-lipid conjugates and provides various linkage groups (such as amide group) for conjugating peptide, spacer and lipid, wherein the spacer may comprise PEG. Several advantages can be achieved, such as the synthetic procedure can be simplified, the synthesis process can be set to automation, the purification is easier in each reaction step, and the product losses can be reduced to minimal during synthesis. The present synthesis method is suitable for preparing a wide range of peptide-spacer-lipid conjugates, provides a peptide-spacer-lipid conjugate prepared by the solid phase synthesis method of the present invention, which can be incorporated into a liposome as the targeting moiety for liposomal drug delivery to specific cells, and provides a targeting liposome containing the present peptide-spacer-lipid conjugate.

1 . A solid phase synthesis method for preparing a peptide-spacer-lipid conjugate comprises the steps of: 
 (1) synthesizing an amino acid residue protected peptidyl resin in solid phase;    (2) conjugating a spacer and a lipid to the peptidyl resin, thereby forming a peptide-spacer-lipid resin having a peptide-spacer-lipid;    (3) cleaving the peptide-spacer-lipid from the peptide-spacer-lipid resin;    (4) removing at least one side chain protecting group from at least one amino acid of the peptide-spacer-lipid, thereby forming a peptide-spacer-lipid conjugate; and    (5) subjecting the peptide-spacer-lipid conjugate to a process selected from a group consisting essentially of: 
 (a) no further processing,  
 (b) modifying a peptide portion of the peptide-spacer-lipid conjugate to a cyclic form during any of the foregoing steps (1)-(4), and  
 (c) modifying a peptide portion of the peptide-spacer-lipid conjugate to a cyclic form after any of the foregoing steps (1)- (4),  
   wherein the spacer comprises conjugating to a component selected from a group consisting essentially of the peptidyl resin and the lipid by one linkage functional group.    
   
   
       2 . The method according to  claim 1 , wherein the peptidyl resin comprises synthesized by a process selected from a group consisting essentially of a Fmoc solid phase peptide synthesis technique and a Boc Solid phase peptide synthesis technique.  
   
   
       3 . The method, as recited in  claim 1 , wherein the peptide-spacer-lipid resin comprises forming by conjugating a spacer to the peptidyl resin to obtain a spacer-peptidyl resin and by subsequently conjugating a lipid to the spacer-peptidyl resin.  
   
   
       4 . The method, as recited in  claim 1 , wherein the peptide-spacer-lipid resin comprises forming by conjugating a spacer-lipid to the peptidyl resin.  
   
   
       5 . The method, as recited in  claim 1 , wherein the spacer comprises a linear hydrophilic polymer chain.  
   
   
       6 . The method, as recited in  claim 5 , wherein the spacer comprises at least one compound selected from a group consisting essentially of polyglycine, polyethyleneglycol, polypropyleneglycol, polymethacrylamide, polydimethacrylamide, polyhydroxyethylacrylate, polyhydroxypropylmethacrylate, polyoxyalkene, and hydrophilic-peptides.  
   
   
       7 . The method, as recited in  claim 6 , wherein the spacer comprises polyethylene glycol having an average molecular weight in a range of approximately 100 to approximately 10,000 daltons.  
   
   
       8 . The method, as recited in  claim 1 , wherein the linkage functional group comprises a component selected from the group consisting essentially of an amine, a urethane, an amide, a thio ester, and a thio ether.  
   
   
       9 . The method, as recited in  claim 8 , wherein the linkage functional group comprises an amide.  
   
   
       10 . The method, as recited in  claim 9 , wherein the amide bond comprises forming by an activating agent selected from a group consisting essentially of dicyclohexylcarbodiimide/N-hydroxybenzotriazole (DCC/HOBt), 1,3-diisopropylcarbodiimide/N-hydroxybenzotriazole (DIPCDI/HOBt), and 1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide/N-hydroxysuccinimide (EDC/HOSu).  
   
   
       11 . The method, as recited in  claim 9 , wherein the amide bond comprises forming in at least one solvent selected from a group consisting essentially of DCM, CHCl 3 , DMF, THF.  
   
   
       12 . The method, as recited in  claim 9 , wherein the amide bond comprises forming in a temperature range of approximately 20° C. to approximately 90° C.  
   
   
       13 . The method, as recited in  claim 1 , wherein the cyclic form of the peptide portion comprises forming by an intramolecular linkage between a pair of components selected from a group consisting essentially of two amino acids and at least one derivative of two amino acids.  
   
   
       14 . The method according to  claim 13 , wherein the intramolecular linkage is selected from a group consisting essentially of disulfide, amide, ester, thioether, thioacetate, and thioacetamine.  
   
   
       15 . A peptide-spacer-lipid conjugate synthesized by the method, as recited in  claim 1 .  
   
   
       16 . The peptide-spacer-lipid conjugate, as recited in  claim 15 , wherein the peptide comprises a peptide ligand component selected from a group consisting essentially of a peptide ligand and peptide ligand mimetic.  
   
   
       17 . The peptide-spacer-lipid conjugate, as recited in  claim 16 , wherein the peptide ligand component is bound to a receptor.  
   
   
       18 . The peptide-spacer-lipid conjugate, recited in  claim 17 , wherein the receptor is a component selected from a group essentially of a somatostatin receptors, a vasoactive intestinal peptide receptors, an integrin receptors, a fibroblast growth factor receptors, a hepatocyte growth factor receptor, epidermal growth factor receptor, an insulin-like growth factor receptor, a nerve growth factor receptor, a vascular endothelial growth factor receptor, a platelet-derived growth factor receptors, and a transforming growth factor receptor.  
   
   
       19 . The peptide-spacer-lipid conjugate, as recited in  claim 16 , wherein the peptide ligand component comprises at least one material selected from a group consisting essentially of a hormone, a chemotaxin, a cytokine, a toxin, and a peptide of an extracellular matrix for cell adhesion.  
   
   
       20 . The peptide-spacer-lipid conjugate, as recited in  claim 19 , wherein the peptide ligand component comprises at least one material selected form a group consisting essentially of a somatostatin, vasoactive intestinal peptide, an integrin binding inhibitors, a fibroblast growth factors, a hepatocyte growth factor, an epidermal growth factor, a laminin binding inhibitor, a nerve growth factor, a fibronectin, a fibroblast growth factor, a insulin-like growth factors, a vascular endothelial growth factor, a platelet-derived growth factors, and a transforming growth factor.  
   
   
       21 . The peptide-spacer-lipid conjugate, recited in  claim 20 , wherein the peptide ligand component comprises at least one material selected form the group consisting essentially of:  
     
       
         
               
               
             
                   
               
                 H-Cys(Acm)-Met-His-Ile-Glu-Ser-Leu-Asp-Ser-Tyr- 
                   
               
                 Thr-Cys(Acm)-OH, 
               
                   
               
                 H-Phe-Asn-Leu-Pro-Leu-Gly-Asn-Tyr-Lys-Lys-Pro-OH, 
               
                   
               
                 H-Leu-Gly-Thr-Ile-Pro-Gly-OH, 
               
                   
               
                 H-Gly-Arg-Gly-Glu-Ser-OH, 
               
                   
               
                 H-Glu-Ile-Leu-Asp-Val-OH, 
               
                   
               
                 H-Lys-Arg-Thr-Gly-Gln-Tyr-Lys-Leu-OH, 
               
                   
               
                 H-Gly-Tyr-Gly-Ser-Ser-Ser-Arg-Arg-Ala-Pro-Gln-Thr- 
               
                 OH,  
               
                   
               
                 H-Gly-His-Lys-OH, 
               
                   
               
                 H-Pro-Glu-Ala-His-Trp-Thr-Lys-Leu-Gln-His-Ser-Leu- 
               
                 Asp-Thr-Ala-Leu-Arg-OH 
               
                   
               
                 cyclic H- (D)Phe-Cys-Phe-(D)Trp-Lys-Thr-Cys- 
               
                 Thr(ol), 
               
                 and 
               
                   
               
                 cyclic H- (D)Phe-Cys-Phe-Gly-Lys-Thr-Cys-Thr(ol). 
               
                   
               
           
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
             
          
         
       
     
   
   
       22 . The peptide-spacer-lipid conjugate, as recited in  claim 21 , wherein the conjugate is:  
     
       
         
               
               
             
                   
               
                 cyclo-DSPE-NHC(O)-PEG 600 -C(O)NH-(D)Phe-C ys-Phe-   
                   
               
                   (D)Trp-Lys-Thr-Cy s-Thr-ol (c-OPD 600 ); 
               
                   
               
                 cyclo-DSPE-NHC(O)-PEG 2000 -C(O)NH-(D)Phe-C ys-Phe-   
               
                   (D)Trp-Lys-Thr-Cy s-Thr-ol (c-OPD2 000 ); 
               
                   
               
                 cyclo-DSPE-NHC(O)-PEG 3000 -C(O)NH-(D)Phe-C ys-Phe-   
               
                   (D)Trp-Lys-Thr-Cy s-Thr-ol (c-OPD 3000 ); 
               
                   
               
                 DSPE-NHC(O)-PEG 2000 -C(O)NH-Gly-Arg-Gly-Asp-Ser- 
               
                 Gly-ol;  
               
                   
               
                 DSPE-NHC(O)-PEG 2000 -C(O)NH-Gly-His-Lys-Gly-ol; 
               
                 or 
               
                   
               
                 DSPE-NHC(O)-PEG 2000 -C(O)NH-Cys(Asm)-Met-His-Ile- 
               
                 Glu-Ser-Leu-Asp-Ser-Tyr-Thr-Cys(Acm)-Gly-ol. 
               
                   
               
           
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
             
          
         
       
     
   
   
       23 . The peptide-spacer-lipid conjugate, as recited in  claim 15 , wherein the lipid comprises a phospholipid selected from a group consisting essentially of a phosphodiglyceride and a sphingolipid.  
   
   
       24 . A targeted therapeutic liposome comprising the peptide-spacer-lipid conjugate, as recited in  claim 15 .  
   
   
       25 . The targeted therapeutic liposome, as recited in  claim 24 , wherein the peptide-spacer-lipid conjugate is cyclo-DSPE-NHC(O)-PEG-C(O)NH-(D)Phe-C ys-Phe-(D)Trp-Lys-Thr-Cy s-Thr-ol (c-OPD).  
   
   
       26 . The targeted therapeutic liposome, as recited in  claim 24 , wherein an agent component selected from a group consisting essentially of a therapeutic agent for treating a disease and a diagnostic agent for diagnosing a disease, and wherein the agent component is entrapped.  
   
   
       27 . The targeted therapeutic liposome, as recited in  claim 26 , wherein the disease is somatostatin receptor expressed cancer.  
   
   
       28 . A peptide-spacer-lipid conjugate synthesized by the method, as recited in  claim 2 .  
   
   
       29 . A peptide-spacer-lipid conjugate synthesized by the method, as recited in  claim 3 .  
   
   
       30 . A peptide-spacer-lipid conjugate synthesized by the method, as recited in  claim 4 .  
   
   
       31 . A peptide-spacer-lipid conjugate synthesized by the method, as recited in  claim 5 .  
   
   
       32 . A peptide-spacer-lipid conjugate synthesized by the method, as recited in  claim 6 .  
   
   
       33 . A peptide-spacer-lipid conjugate synthesized by the method, as recited in  claim 7 .  
   
   
       34 . A peptide-spacer-lipid conjugate synthesized by the method, as recited in  claim 8 .  
   
   
       35 . A peptide-spacer-lipid conjugate synthesized by the method, as recited in  claim 9 .  
   
   
       36 . A peptide-spacer-lipid conjugate synthesized by the method, as recited in  claim 10 .  
   
   
       37 . A peptide-spacer-lipid conjugate synthesized by the method, as recited in  claim 11 .  
   
   
       38 . A peptide-spacer-lipid conjugate synthesized by the method, as recited in  claim 12 .  
   
   
       39 . A peptide-spacer-lipid conjugate synthesized by the method, as recited in  claim 13 .  
   
   
       40 . A peptide-spacer-lipid conjugate synthesized by the method, as recited in  claim 14 .  
   
   
       41 .- 50 . (canceled)